[{"id":"c4a67b85-d57e-45f1-9a88-e437704888be","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479306","created_at":"2021-01-18T21:30:41.583Z","updated_at":"2024-07-02T16:34:59.204Z","phase":"Phase 1","brief_title":"Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04479306","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • sapanisertib (CB-228) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 07/27/2023","primary_completion_date":" 07/27/2023","study_txt":" Completion: 07/27/2023","study_completion_date":" 07/27/2023","last_update_posted":"2024-06-04"},{"id":"1427eec4-ad27-4c77-af5b-007ed81dc9bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541407","created_at":"2021-01-18T21:43:42.871Z","updated_at":"2024-07-02T16:35:47.920Z","phase":"Phase 1","brief_title":"Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease","source_id_and_acronym":"NCT04541407","lead_sponsor":"University of Colorado, Denver","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L858R + EGFR exon 21 deletion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L858R + EGFR exon 21 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • temozolomide • Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 10/29/2020","start_date":" 10/29/2020","primary_txt":" Primary completion: 04/25/2022","primary_completion_date":" 04/25/2022","study_txt":" Completion: 06/07/2022","study_completion_date":" 06/07/2022","last_update_posted":"2023-05-16"},{"id":"5220a271-34bc-4ab0-b9c9-72c254137fa8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04988607","created_at":"2021-08-03T18:53:07.867Z","updated_at":"2024-07-02T16:36:26.978Z","phase":"Phase 2","brief_title":"Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC","source_id_and_acronym":"NCT04988607","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR L858R + EGFR exon 21 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR L858R + EGFR exon 21 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2021-08-03"}]